 | |
| Identifiers | |
|---|---|
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C17H22O2 |
| Molar mass | 258.361 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
O-1602 is a synthetic compound most closely related toabnormal cannabidiol, and more distantly related in structure tocannabinoid drugs such asTHC. O-1602 does not bind to the classicalcannabinoid receptors CB1 or CB2 with any significant affinity, but instead is an agonist at several other receptors which appear to be related to the cannabinoid receptors, particularlyGPR18 andGPR55. These previouslyorphan receptors have been found to be targets for a number of endogenous and synthetic cannabinoid compounds, and are thought to be responsible for most of the non-CB1, non-CB2 mediated effects that have become evident in the course of cannabinoid research. O-1602 produces some effects shared with classical cannabinoid compounds such asanalgesic andantiinflammatory effects and appetite stimulation, but it does not produce sedation or psychoactive effects, and has several actions in the gut and brain that are not shared with typical cannabinoid agonists.[1][2][3][4][5][6][7]
